Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 2, 2014, Pages 387-397

  Hua, Kuo Tai ^a   Lee, Wei Jiunn ^b   Yang, Shun Fa ^c,d   Chen, Chi Kuan ^a   Hsiao, Michael ^e   Ku, Chia Chi ^b   Wei, Lin Hung ^f   Kuo, Min Liang ^a,g   Chien, Ming Hsien ^b,h  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AML; Chemoresistance; Cyclooxygenase 2; Endothelin 1; VEGF C

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOOXYGENASE 2; CYTARABINE; EDN1 PROTEIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ETOPOSIDE; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 3; PROTEIN P27; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ACUTE MYELOID LEUKEMIA; AML; CDK; CHEMORESISTANCE; CKIS; COX; CYCLIN-DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE INHIBITORS; CYCLOOXYGENASE; CYCLOOXYGENASE-2; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; ENDOTHELIN-1; ET-1; ETRA; ETRB; VASCULAR ENDOTHELIAL GROWTH FACTOR-C; VEGF-C;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN-1; ENZYME INDUCTION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84890734854     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.10.015     Document Type: Article

References (53)

1. Wellbrock J., Fiedler W. Clinical experience with antiangiogenic therapy in leukemia. Curr. Cancer Drug Targets 2011, 11:1053-1068.
2. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:1751.
3. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122:3829-3837.
4. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14389-14394.
5. Lee J., Gray A., Yuan J., Luoh S.M., Avraham H., Wood W.I. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1988-1992.
6. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S., Wilting J., Sleeman J.P. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 2003, 63:713-722.
7. Takizawa H., Kondo K., Fujino H., Kenzaki K., Miyoshi T., Sakiyama S., Tangoku A. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br. J. Cancer 2006, 95:75-79.
8. Su J.L., Yang P.C., Shih J.Y., Yang C.Y., Wei L.H., Hsieh C.Y., Chou C.H., Jeng Y.M., Wang M.Y., Chang K.J., Hung M.C., Kuo M.L. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006, 9:209-223.
9. Appelbaum F.R., Rowe J.M., Radich J., Dick J.E. Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2001, 62-86.
10. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99:2179-2184.
11. Fielder W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., Hossfeld D.K. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11:1234-1237.
12. Liersch R., Schliemann C., Bieker R., Hintelmann H., Buechner T., Berdel W.E., Mesters R.M. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk. Res. 2008, 32:954-961.
13. Chien M.H., Ku C.C., Johansson G., Chen M.W., Hsiao M., Su J.L., Inoue H., Hua K.T., Wei L.H., Kuo M.L. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 2009, 30:2005-2013.
14. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 2002, 161:947-956.
15. Koyama H., Kobayashi N., Harada M., Takeoka M., Kawai Y., Sano K., Fujimori M., Amano J., Ohhashi T., Kannagi R., Kimata K., Taniguchi S., Itano N. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am. J. Pathol. 2008, 172:179-193.
16. de Jonge H.J., Valk P.J., Veeger N.J., ter Elst A., den Boer M.L., Cloos J., de Haas V., van den Heuvel-Eibrink M.M., Kaspers G.J., Zwaan C.M., Kamps W.A., Lowenberg B., de Bont E.S. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116:1747-1754.
17. de Jonge H.J., Weidenaar A.C., Ter Elst A., Boezen H.M., Scherpen F.J., Bouma-Ter Steege J.C., Kaspers G.J., Goemans B.F., Creutzig U., Zimmermann M., Kamps W.A., de Bont E.S. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin. Cancer Res. 2008, 14:924-930.
18. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
19. Tjiu J.W., Liao Y.H., Lin S.J., Huang Y.L., Tsai W.L., Chu C.Y., Kuo M.L., Jee S.H. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J. Invest. Dermatol. 2006, 126:1143-1151.
20. Lin S.Y., Liu J.D., Chang H.C., Yeh S.D., Lin C.H., Lee W.S. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J. Cell. Biochem. 2002, 84:532-544.
21. Cursiefen C., Schlotzer-Schrehardt U., Kuchle M., Sorokin L., Breiteneder-Geleff S., Alitalo K., Jackson D. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest. Ophthalmol. Vis. Sci. 2002, 43:2127-2135.
22. Tourneur L., Delluc S., Levy V., Valensi F., Radford-Weiss I., Legrand O., Vargaftig J., Boix C., Macintyre E.A., Varet B., Chiocchia G., Buzyn A. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res. 2004, 64:8101-8108.
23. Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 2003, 3:110-116.
24. Peng H., Chen P., Cai Y., Chen Y., Wu Q.H., Li Y., Zhou R., Fang X. Endothelin-1 increases expression of cyclooxygenase-2 and production of interlukin-8 in human pulmonary epithelial cells. Peptides 2008, 29:419-424.
25. Spinella F., Rosano L., Di Castro V., Decandia S., Nicotra M.R., Natali P.G., Bagnato A. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res. 2007, 67:1725-1734.
26. Lin C.C., Hsieh H.L., Shih R.H., Chi P.L., Cheng S.E., Yang C.M. Up-regulation of COX-2/PGE2 by endothelin-1 via MAPK-dependent NF-kappaB pathway in mouse brain microvascular endothelial cells. Cell Commun. Signal.: CCS 2013, 11:8.
27. Su Q., Jia R.P., Lin J., Xu L.W., Wang Z.Z., Li W.C., Wang S.K. Effect of endothelin-1 on cyclooxygenase-2 expression in human hormone refractory prostate cancer cells. Oncol. Lett. 2010, 1:495-499.
28. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 1993, 4:327-332.
29. Kay N.E., Bone N.D., Tschumper R.C., Howell K.H., Geyer S.M., Dewald G.W., Hanson C.A., Jelinek D.F. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002, 16:911-919.
30. Oikawa T., Kushuhara M., Ishikawa S., Hitomi J., Kono A., Iwanaga T., Yamaguchi K. Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells. Br. J. Cancer 1994, 69:1059-1064.
31. Said N., Smith S., Sanchez-Carbayo M., Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 2011, 121:132-147.
32. Boldrini L., Gisfredi S., Ursino S., Faviana P., Lucchi M., Melfi F., Mussi A., Basolo F., Fontanini G. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur. J. Cancer 2005, 41:2828-2835.
33. Mathieu M.N., Vittet D., Laliberte M.F., Laliberte F., Nonotte I., Hamroun D., Launay J.M., Chevillard C. Endothelin expression in human megakaryoblastic leukemia cell lines and normal platelet precursors. Regul. Pept. 1997, 68:91-97.
34. Deacon K., Knox A.J. Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop. J. Biol. Chem. 2010, 285:25913-25927.
35. Wang H.H., Hsieh H.L., Wu C.Y., Yang C.M. Endothelin-1 enhances cell migration via matrix metalloproteinase-9 up-regulation in brain astrocytes. J. Neurochem. 2010, 113:1133-1149.
36. Wu M.H., Chen L.M., Hsu H.H., Lin J.A., Lin Y.M., Tsai F.J., Tsai C.H., Huang C.Y., Tang C.H. Endothelin-1 enhances cell migration through COX-2 up-regulation in human chondrosarcoma. Biochim. Biophys. Acta 2013, 1830:3355-3364.
37. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437:169-183.
38. Stow L.R., Jacobs M.E., Wingo C.S., Cain B.D. Endothelin-1 gene regulation. FASEB J. 2011, 25:16-28.
39. Rubanyi G.M., Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 1994, 46:325-415.
40. Davenport A.P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 2002, 54:219-226.
41. Bagnato A., Rosano L. The endothelin axis in cancer. Int. J. Biochem. Cell Biol. 2008, 40:1443-1451.
42. Okazawa M., Shiraki T., Ninomiya H., Kobayashi S., Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J. Biol. Chem. 1998, 273:12584-12592.
43. Nelson J.B., Chan-Tack K., Hedican S.P., Magnuson S.R., Opgenorth T.J., Bova G.S., Simons J.W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer research 1996, 56:663-668.
44. Nelson J.B., Lee W.H., Nguyen S.H., Jarrard D.F., Brooks J.D., Magnuson S.R., Opgenorth T.J., Nelson W.G., Bova G.S. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer research 1997, 57:35-37.
45. Pao M.M., Tsutsumi M., Liang G., Uzvolgyi E., Gonzales F.A., Jones P.A. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum. Mol. Genet. 2001, 10:903-910.
46. Hsiao P.C., Liu M.C., Chen L.M., Tsai C.Y., Wang Y.T., Chen J., Hsu L.S. Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan. Chin. J. Physiol. 2008, 51:27-31.
47. Lahav R. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int. J. Dev. Biol. 2005, 49:173-180.
48. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., Chen H.Y., Hung M.C., Kuo M.L. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br. J. Cancer 2007, 96:541-545.
49. Clinical Experience with Antiangiogenic Therapy in LeukemiaDeng X., Kornblau S.M., Ruvolo P.P., May W.S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J. Natl. Cancer Inst. Monogr. 2001, 30-37.
50. Liu B., Qu L., Tao H. Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell biology international 2010, 34:21-25.
51. Xin X., Majumder M., Girish G.V., Mohindra V., Maruyama T., Lala P.K. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab. Invest. 2012, 92:1115-1128.
52. Su J.L., Shih J.Y., Yen M.L., Jeng Y.M., Chang C.C., Hsieh C.Y., Wei L.H., Yang P.C., Kuo M.L. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer research 2004, 64:554-564.
53. Timoshenko A.V., Chakraborty C., Wagner G.F., Lala P.K. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br. J. Cancer 2006, 94:1154-1163.